170. Eur J Clin Pharmacol. 2018 Jun 16. doi: 10.1007/s00228-018-2503-8. [Epub ahead ofprint]Population pharmacokinetic model for tumescent lidocaine in women undergoingbreast cancer surgery.Riff C(1)(2), Bourgoin A(3), Marsot A(4)(5), Allanioux L(4), Leone M(3), BlinO(4)(5), Guilhaumou R(4).Author information: (1)Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital de la Timone, AP-HM, 13385, Marseille, France. camille.riff@gmail.com.(2)Pharmacologie Intégrée et Interface Clinique Industrielle, Institut desNeurosciences Timone - AMU-CNRS 7289, Aix-Marseille Université, 13385, Marseille,France. camille.riff@gmail.com.(3)Aix Marseille Université, Service d'Anesthésie-Réanimation, Hôpital Nord,Assistance Publique des Hôpitaux de Marseille, APHM, Marseille, France.(4)Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital de la Timone, AP-HM, 13385, Marseille, France.(5)Pharmacologie Intégrée et Interface Clinique Industrielle, Institut desNeurosciences Timone - AMU-CNRS 7289, Aix-Marseille Université, 13385, Marseille,France.PURPOSE: Tumescent lidocaine anesthesia (TLA) is an opportunity to performmastectomy for breast cancer without general anesthesia in elderly women. Fewreports are available on the pharmacokinetics of lidocaine in a context of TLAduring a unilateral mastectomy. The aim of this study was to describe lidocainepharmacokinetics in elderly women undergoing breast cancer surgery after TLA and to explore the risk of the toxicity of this technique.METHODS: A prospective study was conducted to examine the pharmacokinetics oflidocaine in women undergoing TLA. TLA consists of an intradermal lidocaineinstillation (20 mL, 1% [200 mg]) followed by a tumescent lidocaine infiltration (100 mL of 1% lidocaine [1000 mg] and 0.5 mg epinephrine to 1 L Ringer's lactate)via an infusion pump. A population pharmacokinetic (popPK) analysis was performedusing the nonlinear mixed effects model (NONMEM).RESULTS: The analysis included 116 observations from 17 women with a median(range) age of 83.4 (60.5-90.0). The median tumescent lidocaine dose was 800 mg(range 375-1000 mg) infused over 48.0 ± 11.0 min. A one-compartment dispositionmodel with first order absorption, two input compartments, and a centralelimination best described the pharmacokinetics of lidocaine. The estimates(between subject variability; relative standard error, %) of apparent volume,apparent clearance, tumescent absorption rate, and instillation absorption ratewere 195.0 (46.3; 14.5%) L, 24.7 (48.9; 13.3%) L h-1, 0.28 (39.6; 13.8%) h-1, and2.56 (135.3; 44.9%) h-1, respectively.CONCLUSIONS: This is the first popPK model developed to describe kinetic profilesof TLA. These findings confirm the slow diffusion of lidocaine from the tumescentdeposit.DOI: 10.1007/s00228-018-2503-8 PMID: 29909577 